David Hoang
Stock Analyst at Deutsche Bank
(3.64)
# 784
Out of 5,156 analysts
47
Total ratings
48.65%
Success rate
9.41%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Buy | $103 | $74.94 | +37.44% | 1 | Dec 10, 2025 | |
| ALKS Alkermes | Maintains: Buy | $55 → $45 | $28.45 | +58.17% | 3 | Nov 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $280 | $309.01 | -9.39% | 2 | Oct 17, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Buy | $43 | $41.07 | +4.70% | 1 | Sep 26, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $36 | $28.57 | +26.01% | 4 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sell | $6 → $12 | $17.64 | -31.97% | 10 | Aug 15, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $22.58 | +55.00% | 5 | May 21, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $62.76 | +6.76% | 3 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $21.31 | +45.47% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $10.21 | +536.63% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $176 | $164.49 | +7.00% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $129.93 | +21.60% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $3.14 | +122.93% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $8.02 | +99.50% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.11 | +289.29% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $323.59 | -32.01% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $60.67 | +31.86% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $0.56 | +440.25% | 1 | Dec 7, 2022 |
Apogee Therapeutics
Dec 10, 2025
Initiates: Buy
Price Target: $103
Current: $74.94
Upside: +37.44%
Alkermes
Nov 13, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $28.45
Upside: +58.17%
Praxis Precision Medicines
Oct 17, 2025
Maintains: Buy
Price Target: $65 → $280
Current: $309.01
Upside: -9.39%
Spyre Therapeutics
Sep 26, 2025
Initiates: Buy
Price Target: $43
Current: $41.07
Upside: +4.70%
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Buy
Price Target: $54 → $36
Current: $28.57
Upside: +26.01%
Sarepta Therapeutics
Aug 15, 2025
Maintains: Sell
Price Target: $6 → $12
Current: $17.64
Upside: -31.97%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $22.58
Upside: +55.00%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $62.76
Upside: +6.76%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $21.31
Upside: +45.47%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $10.21
Upside: +536.63%
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $164.49
Upside: +7.00%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $129.93
Upside: +21.60%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $3.14
Upside: +122.93%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $8.02
Upside: +99.50%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $4.11
Upside: +289.29%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $323.59
Upside: -32.01%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $60.67
Upside: +31.86%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $0.56
Upside: +440.25%